Tecelra, developed by biopharmaceutical company Adaptimmune, is the first gene therapy treatment for adult patients with unresectable or metastatic synovial sarcoma to be approved by the FDA, according to an Aug. 2 news release from the agency.
Synovial sarcoma affects around 1,000 people in the U.S. every year and occurs most frequently with males in their 30s and younger.
Treatment for synovial sarcoma usually involves surgery or a combination of radiotherapy/chemotherapy and surgery for certain tumors or disease spread. Tecelra is administered in a single intravenous dose, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
